home / stock / xyno / xyno quote
Last: | $2.22 |
---|---|
Change Percent: | 0.0% |
Open: | $2.22 |
Close: | $2.22 |
High: | $2.22 |
Low: | $2.22 |
Volume: | 132 |
Last Trade Date Time: | 05/12/2021 04:56:18 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.22 | $2.22 | $2.22 | $2.22 | $2.22 | 132 | 05-12-2021 |
$2.16 | $2.16 | $2.16 | $2.16 | $2.16 | 131 | 04-14-2021 |
$2.08 | $2.08 | $2.08 | $2.08 | $2.08 | 1,000 | 03-22-2021 |
$2.33 | $2.33 | $2.33 | $2.33 | $2.33 | 100 | 02-25-2021 |
$2.5 | $2.5 | $2.5 | $2.5 | $2.5 | 320 | 02-23-2021 |
$2.5 | $2.1 | $2.5 | $2.5 | $2.1 | 1,580 | 02-17-2021 |
$2.85 | $2 | $2.85 | $2.85 | $2 | 3,123 | 02-05-2021 |
$2 | $3.5 | $2 | $3.5 | $2 | 506 | 02-04-2021 |
$3.77 | $3.79 | $3.77 | $3.79 | $3.77 | 732 | 01-29-2021 |
$1.7 | $2.26 | $1.7 | $2.26 | $1.7 | 2,500 | 01-26-2021 |
$2.41 | $2.41 | $2.41 | $2.41 | $2.41 | 200 | 01-13-2021 |
$2.41 | $2.21 | $2.41 | $2.41 | $2.21 | 460 | 01-08-2021 |
$2.01 | $2.85 | $2.01 | $2.85 | $1.74 | 4,600 | 01-01-2021 |
$2.01 | $2.85 | $2.01 | $2.85 | $1.74 | 4,600 | 12-31-2020 |
$3.84 | $3.84 | $3.84 | $3.84 | $3.84 | 230 | 12-30-2020 |
$3.84 | $3.1 | $3.84 | $3.84 | $3.1 | 8,970 | 12-29-2020 |
$2.62 | $2.62 | $2.62 | $2.62 | $2.62 | 100 | 12-23-2020 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 237 | 11-30-2020 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 129 | 11-17-2020 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 531 | 11-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc Company Name:
XYNO Stock Symbol:
OTCMKTS Market:
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...